There is an assumption among posters that unless favorable patient selection takes place or more favorable aipc patients enter the trial, the impact trial will fail. Its not necessarily true. Posters seem to jump on the bandwagon and assume the theoretical but unproven argument that immunotherapy works best in earlier diseaseis is gospel/. That is just a hypothesis. I feel comfortable with the present patient selection As long as the placebo group and treatment groups are balanced. In the meantime we just sit back and await more data.
>The Halabi data presented today were probably generated when the enrollment number was somewhere below 400. So that could be skewed due to early 9902b enrollees who were relatively healthier than D9901.<
You could be right, but Gold did not say—or imply—that the Halabi median value disclosed on the webcast was somewhat out of date.
Since the Halabi output for 9902b is based on blinded patient data only, one would think that DNDN could have obtained numbers that were fully up to date.
Market Data 
Markets 
AI
